Medical Health Cluster

Nonhospitalized

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

Nirmatrelvir is an orally administered severe acute respiratory syndrome coronavirus 2 main protease (Mpro) inhibitor with potent pan–human-coronavirus activity in vitro. METHODS We conducted a phase 2–3 double-blind, randomized, controlled trial in which symptomatic, unvaccinated, nonhospitalized adults at high risk for progression to severe coronavirus disease 2019 (Covid-19) were assigned […]

Read More

The COVID-19 Treatment Guidelines Panel’s Statement on Therapies for High-Risk, Nonhospitalized Patients With Mild to Moderate COVID-19

The following statement is an updated version of the statement that the COVID-19 Treatment Guidelines Panel (the Panel) released on December 30, 2021. This update addresses the fact that the B.1.1.529 (Omicron) variant of concern (VOC) is now the dominant SARS-CoV-2 variant in all 10 of the Department of Health and […]

Read More